| Catalog No. | Size | Price (USD) |
| 203014-T08-50 | 50 µL | $147.96 |
| 203014-T08-100 | 100 µL | $251.64 |
| 203014-T08-200 | 200 µL | $355.32 |
General Information
| Product name | Anti-ACSL5 Antibody, Rabbit Polyclonal |
| Validated applications | IHC-P (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human ACSL5 |
| Immunogen | E. coli-derived Human ACSL5 fragment |
| Preparation | Produced in rabbits immunized with E. coli-derived Human ACSL5 fragment, and purified by antigen affinity chromatography. |
| Source | Polyclonal Rabbit IgG |
| Purification | Protein A & Antigen Affinity |
| Formulation | PBS, pH7.0 with 0.03% Proclin300 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-ACS2 Antibody; Anti-ACS5 Antibody; Anti-DIAR13 Antibody; Anti-FACL5 Antibody; Anti-UNQ633/PRO1250 Antibody
Image / Experimental Information
| Image 1 Description | Immunochemical staining of human ACSL5 in human liver with rabbit polyclonal antibody at 1:100 dilution, formalin-fixed paraffin embedded sections. |
| Image 1 Alt Text | Human ACSL5 Immunohistochemistry(IHC) 22013 |
| Image 1 URL | Source image |
Background Information
| Full Name | acyl-CoA synthetase long-chain family member 5 |
| Description | Long-chain acyl-CoA synthetases (ACSLs) activate fatty acids (FAs: C12-C20), by thioesterification with Coenzyme A (CoA), generating FA-CoAs. Acyl-CoA synthetase 5 (ACSL5), a mitochondrially localized enzyme, catalyzes the synthesis of long-chain fatty acid thioesters and is physiologically involved in pro-apoptotic sensing of enterocytes. ACSL5 is implicated in several types of cancers and has a potential prognostic value. Unlike other ACSLs, ACSL5 is downregulated in colorectal carcinomas, breast, bladder, and pancreas. However, ACSL5 is overexpressed in glioma and considered a potential therapeutic target. Besides, the fibroblast growth factor receptor 2 (FGFR2) ACSL5 chimera RNA rendered clinical gastric cancer cells resistant to treatment with FGFR inhibitors. |
| References |
|
-HD12JL1744-100-human-liver-IHC-P.png){kind=link}